704 results on '"A. Kirk"'
Search Results
2. Accelerated Allograft Vasculopathy With Rituximab After Cardiac Transplantation
3. TCT-708 5-Year Outcomes of Patients With Diabetes Mellitus Treated With a Sirolimus-Eluting or a Biolimus-Eluting Stent With Biodegradable Polymer: From the SORT OUT VII Trial
4. Ventricular Assist Device Support as a Bridge to Transplantation in Pediatric Patients
5. Correction
6. MAJOR OUTCOMES IN CRITICAL LIMB ISCHEMIA PATIENTS WITH END STAGE KIDNEY DISEASE: AN ANALYSIS FROM USRDS DATABASE
7. IMPACT OF THE COVID PANDEMIC ON DEPRESSIVE SYMPTOMS AND SEVERITY
8. A COMPARISON OF CARDIOVASCULAR OUTCOMES AMONG SARS-COV-2 POSITIVE PATIENTS, SARS-COV-2 NEGATIVE PATIENTS, AND A HISTORICAL COHORT
9. THE EFFECT OF TRANS-CATHETER AORTIC VALVE REPLACEMENT ON SURGICAL AORTIC VALVE REPLACEMENT
10. SUPERIOR TRANSSEPTAL ACCESS FOR ABLATION OF ATRIAL FIBRILLATION
11. IS EXPOSURE TO EPSTEIN-BARR VIRUS A RISK FACTOR FOR LONG-COVID?
12. MEASURING APOLIPOPROTEIN B100 (APO B) IN CLINICAL PRACTICE: EPIDEMIOLOGY, FREQUENCY OF TESTING, AND RELATIONSHIP TO LDL-C
13. ROUTINE PERIODIC FASTING IS ASSOCIATED WITH A LOWER RISK OF INPATIENT HOSPITALIZATION FOR THE PRIMARY DIAGNOSIS OF HEART FAILURE FOLLOWING COVID-19 DIAGNOSIS
14. ALL-CAUSE MORTALITY AND CARDIOVASCULAR OUTCOMES IN END STAGE KIDNEY DISEASE PATIENTS WITH PERIPHERAL ARTERY AND POLYVASCULAR DISEASE: AN ANALYSIS FROM USRDS DATABASE
15. DISPROPORTIONAL AMOUNT OF CORONARY ARTERY CALCIUM (CAC) IN A VESSEL DOES NOT INCREASE LIKELIHOOD OF MAJOR CARDIOVASCULAR EVENTS (MACE)
16. IMPACT OF ACTIVE VERSUS PASSIVE STATIN SELECTION FOR PRIMARY PREVENTION OF ATHEROSCLEROTIC CARDIOVASCULAR DISEASE (ASCVD): A REPORT FROM THE CORCAL VANGUARD TRIAL
17. MEASURING LIPOPROTEIN(A) IN CLINICAL PRACTICE: EPIDEMIOLOGY, RELATIONSHIP TO ATHEROSCLEROTIC CARDIOVASCULAR (ASCVD) RISK FACTORS, AND CLINICAL OUTCOMES IN A REAL-WORLD EXPERIENCE
18. Cost-Effectiveness of Revascularization Strategies: The ASCERT Study
19. SUPERIOR TRANSSEPTAL ACCESS FOR ABLATION OF ATRIAL FIBRILLATION
20. IMPACT OF ACTIVE VERSUS PASSIVE STATIN SELECTION FOR PRIMARY PREVENTION OF ATHEROSCLEROTIC CARDIOVASCULAR DISEASE (ASCVD): A REPORT FROM THE CORCAL VANGUARD TRIAL
21. MAJOR OUTCOMES IN CRITICAL LIMB ISCHEMIA PATIENTS WITH END STAGE KIDNEY DISEASE: AN ANALYSIS FROM USRDS DATABASE
22. ALL-CAUSE MORTALITY AND CARDIOVASCULAR OUTCOMES IN END STAGE KIDNEY DISEASE PATIENTS WITH PERIPHERAL ARTERY AND POLYVASCULAR DISEASE: AN ANALYSIS FROM USRDS DATABASE
23. THE EFFECT OF TRANS-CATHETER AORTIC VALVE REPLACEMENT ON SURGICAL AORTIC VALVE REPLACEMENT
24. IS EXPOSURE TO EPSTEIN-BARR VIRUS A RISK FACTOR FOR LONG-COVID?
25. IMPACT OF THE COVID PANDEMIC ON DEPRESSIVE SYMPTOMS AND SEVERITY
26. DISPROPORTIONAL AMOUNT OF CORONARY ARTERY CALCIUM (CAC) IN A VESSEL DOES NOT INCREASE LIKELIHOOD OF MAJOR CARDIOVASCULAR EVENTS (MACE)
27. MEASURING LIPOPROTEIN(A) IN CLINICAL PRACTICE: EPIDEMIOLOGY, RELATIONSHIP TO ATHEROSCLEROTIC CARDIOVASCULAR (ASCVD) RISK FACTORS, AND CLINICAL OUTCOMES IN A REAL-WORLD EXPERIENCE
28. ROUTINE PERIODIC FASTING IS ASSOCIATED WITH A LOWER RISK OF INPATIENT HOSPITALIZATION FOR THE PRIMARY DIAGNOSIS OF HEART FAILURE FOLLOWING COVID-19 DIAGNOSIS
29. MEASURING APOLIPOPROTEIN B100 (APO B) IN CLINICAL PRACTICE: EPIDEMIOLOGY, FREQUENCY OF TESTING, AND RELATIONSHIP TO LDL-C
30. A COMPARISON OF CARDIOVASCULAR OUTCOMES AMONG SARS-COV-2 POSITIVE PATIENTS, SARS-COV-2 NEGATIVE PATIENTS, AND A HISTORICAL COHORT
31. CANGRELOR USE PATTERNS AND TRANSITION TO ORAL P2Y12 INHIBITORS AMONG PATIENTS WITH MYOCARDIAL INFARCTION: INITIAL INSIGHTS FROM THE CAMEO (CANGRELOR IN ACUTE MYOCARDIAL INFARCTION: EFFECTIVENESS AND OUTCOMES) REGISTRY
32. IMPACT OF ANTICOAGULATION THERAPY ON THECOGNITIVE DECLINE AND DEMENTIA IN PATIENTS WITH NON-VALVULARATRIALFIBRILLATION (CAF) TRIAL
33. USING QUALITY IMPROVEMENT TOOLS TO DECREASE LENGTH OF STAY AFTER FONTAN SURGERY IN PEDIATRIC PATIENTS WITH SINGLE VENTRICLE - TYPE CONGENITAL HEART DISEASE
34. PHARMACOLOGICAL INHIBITION OF BAG3-HSP70 WITH THE PROPOSED CANCER THERAPEUTIC JG-98 IS TOXIC FOR CARDIOMYOCYTES: IN-VIVO PILOT STUDY
35. CORONARY INVOLVEMENT IN EGPA: EYES DON’T SEE WHAT THE MIND DOESN’T KNOW!
36. INITIAL RESULTS OF A NEW INDEPENDENT DIAGNOSTIC TESTING FACILITY DESIGN FOR PATIENT-GENERATED SMARTPHONE-ECG ARRHYTHMIA DETECTION. THE ALIVECOR-IDTF PROGRAM.
37. COMBINED THERAPY WITH SODIUM-GLUCOSE COTRANSPORTER-2 INHIBITORS (SGLT2I) AND GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS (GLP1-RA)—TOLERABILITY AND CLINICAL IMPACT: THE INTERMOUNTAIN HEALTHCARE REAL WORLD EXPERIENCE
38. CARDIOVASCULAR OUTCOMES OF ST-ELEVATION MYOCARDIAL INFARCTION (STEMI) PATIENTS WITHOUT STANDARD MODIFIABLE RISK FACTORS (SMURF-LESS): THE INTERMOUNTAIN HEALTHCARE EXPERIENCE
39. IS ALCOHOL CONSUMPTION ASSOCIATED WITH A LOWER RISK OF CARDIOVASCULAR EVENTS IN PATIENTS TREATED WITH STATINS? AN OBSERVATIONAL REAL-WORLD EXPERIENCE
40. DECADE LONG TRENDS IN CAROTID REVASCULARIZATION IN END STAGE KIDNEY DISEASE PATIENTS WITH ASYMPTOMATIC CAROTID STENOSIS
41. PROGNOSTIC VALUE OF HOSPITAL FRAILTY RISK SCORE AND CLINICAL OUTCOMES IN PERIPHERAL ARTERIAL DISEASE AND END-STAGE-KIDNEY-DISEASE
42. CHANGES IN LIVER FUNCTION TESTS AFTER INITIATION OF STATINS, PCSK9 INHIBITORS, AND COMBINED THERAPY
43. INTERVENTION TO IMPROVE GUIDELINE-BASED CARE FOR DIABETES AND CARDIOVASCULAR DISEASE IS EFFECTIVE IN BLACK AND HISPANIC POPULATIONS
44. CHARACTERISTICS OF PERSONS WITH TYPE 2 DIABETES AND ATHEROSCLEROTIC CARDIOVASCULAR DISEASE PRESCRIBED SGLT-2I AND/OR GLP-1RA AMONG CARDIOLOGY CLINICS IN THE US: INSIGHTS FROM A LARGE IMPLEMENTATION TRIAL
45. PERSISTENCE AND DISCONTINUATION OF SGLT-2I AND GLP-1RA AMONG PERSONS WITH TYPE 2 DIABETES AND ATHEROSCLEROTIC CARDIOVASCULAR DISEASE TREATED IN US CARDIOLOGY CLINICS: INSIGHTS FROM THE COORDINATE-DIABETES TRIAL
46. PREVALENCE AND ISCHEMIC RISK OF SYMPTOMATIC PATIENTS WITH ZERO CORONARY ARTERY CALCIUM UNDERGOING PET/CT
47. P2Y12 INHIBITOR PRESCRIPTION AFTER MYOCARDIAL INFARCTION IN PATIENTS TREATED WITH CORONARY ARTERY BYPASS GRAFT SURGERY OR MEDICAL THERAPY AFTER IMPLEMENTATION OF THE ACC PATIENT NAVIGATOR PROGRAM: FOCUS MI
48. OUTCOMES OF CAROTID REVASCULARIZATION IN END STAGE KIDNEY DISEASE PATIENTS WITH ASYMPTOMATIC CAROTID STENOSIS
49. Human Oxidation-Specific Antibodies Reduce Foam Cell Formation and Atherosclerosis Progression
50. Adenylyl Cyclase 6 Improves Calcium Uptake and Left Ventricular Function in Aged Hearts
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.